1. Home
  2. AQST vs CGEM Comparison

AQST vs CGEM Comparison

Compare AQST & CGEM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Aquestive Therapeutics Inc.

AQST

Aquestive Therapeutics Inc.

HOLD

Current Price

$3.92

Market Cap

707.6M

Sector

Health Care

ML Signal

HOLD

Logo Cullinan Oncology Inc.

CGEM

Cullinan Oncology Inc.

HOLD

Current Price

$10.89

Market Cap

671.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
AQST
CGEM
Founded
2004
2016
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
707.6M
671.7M
IPO Year
2018
2021

Fundamental Metrics

Financial Performance
Metric
AQST
CGEM
Price
$3.92
$10.89
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
6
8
Target Price
$8.83
$28.13
AVG Volume (30 Days)
4.3M
983.3K
Earning Date
11-05-2025
02-26-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$43,397,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$52.34
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$2.12
$5.68
52 Week High
$7.55
$13.33

Technical Indicators

Market Signals
Indicator
AQST
CGEM
Relative Strength Index (RSI) 22.22 55.31
Support Level $5.86 $9.41
Resistance Level $6.59 $10.70
Average True Range (ATR) 0.32 0.63
MACD -0.13 0.03
Stochastic Oscillator 11.98 67.58

Price Performance

Historical Comparison
AQST
CGEM

About AQST Aquestive Therapeutics Inc.

Aquestive Therapeutics Inc is a specialty pharmaceutical company engaged in developing and commercializing differentiated products to meet medical needs. Its later-stage product pipeline focuses on the treatment of diseases of the Central Nervous System (CNS), and an earlier-stage pipeline for the treatment of severe allergic reactions, including anaphylaxis. Its commercial product portfolio includes Suboxone, Emylif, Ondif and Sympazan. The product pipeline includes Libervant Buccal Film, AQST-108. The majority of its revenue comes from the United States.

About CGEM Cullinan Oncology Inc.

Cullinan Therapeutics Inc is a biopharmaceutical company. It has a diversified portfolio of clinical-stage assets that inhibit key drivers of disease or harness the immune system to eliminate diseased cells in both oncology and autoimmune diseases. Its understanding of oncology, immunology, and translational medicine, creates differentiated ideas, identifies the appropriate targets, and selects the optimal modality to develop transformative therapeutics across a variety of cancer and autoimmune indications. It has one reporting and one operating segment, which is the business of developing immunology and oncology therapies.

Share on Social Networks: